Favrille
Antibody-Drug Conjugate Therapy(Favrille)은 FRα 표적 ADC로, Metastatic Bladder Urothelial Carcinoma; Metastatic Renal Pelvis and Ureter Urothelial Carcinoma 영역에서 개발·상용화 중입니다. 작용기전: ADC, while the AKR1C1-WWP2 axis promotes extracellular vesicle-mediated ADC export and clearance, thereby reducing intracellular payload accumulation. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 7% (ClinicalTrials.gov NCT02302339). PK: t½ 7 h. 차별점: novel target for antibody-drug conjugate therapy for AML.
FRα
Metastatic Bladder Urothelial Carcinoma; Metastatic Renal Pelvis and Ureter Urothelial Carcinoma
Recruiting
ADC) have transformed the treatment of breast cancer
deruxtecan for metastatic breast cancer
linker stability influence ocular toxicity
humanized mouse models, single-cell RNA sequencing, and resistant cell systems, we mapped tumor-state remodel
novel target for antibody-drug conjugate therapy for AML
ADC, while the AKR1C1-WWP2 axis promotes extracellular vesicle-mediated ADC export and clearance, thereby reducing intracellular payload accumulation
antibody-dependent cellular cytotoxicity
Payload Diversification Overcomes Resistance and Guides Sequential Antibody-Drug Conjugate Therapy in Breast Cancer
HER2-positive
resistance to sequential ADC is primarily driven by shared payload mechanisms rather than loss of the target
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Favrille
Antibody-Drug Conjugate Therapy(Favrille)은 FRα 표적 ADC로, Metastatic Bladder Urothelial Carcinoma; Metastatic Renal Pelvis and Ureter Urothelial Carcinoma 영역에서 개발·상용화 중입니다. 작용기전: ADC, while the AKR1C1-WWP2 axis promotes extracellular vesicle-mediated ADC export and clearance, thereby reducing intracellular payload accumulation. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 7% (ClinicalTrials.gov NCT02302339). PK: t½ 7 h. 차별점: novel target for antibody-drug conjugate therapy for AML.
FRα
Metastatic Bladder Urothelial Carcinoma; Metastatic Renal Pelvis and Ureter Urothelial Carcinoma
Recruiting
ADC) have transformed the treatment of breast cancer
deruxtecan for metastatic breast cancer
linker stability influence ocular toxicity
humanized mouse models, single-cell RNA sequencing, and resistant cell systems, we mapped tumor-state remodel
novel target for antibody-drug conjugate therapy for AML
ADC, while the AKR1C1-WWP2 axis promotes extracellular vesicle-mediated ADC export and clearance, thereby reducing intracellular payload accumulation
antibody-dependent cellular cytotoxicity
Payload Diversification Overcomes Resistance and Guides Sequential Antibody-Drug Conjugate Therapy in Breast Cancer
HER2-positive
resistance to sequential ADC is primarily driven by shared payload mechanisms rather than loss of the target
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.